A password will be e-mailed to you.

Experimental Cancer Drug Shows Promise for Parkinson’s

Summary: Tasquinimod, a new cancer drug, appears to control genes associated with Parkinson’s disease, a new study reports.

Source: Oxford University.

The study, funded by Parkinson’s UK, suggests that the drug, tasquinimod, which is not yet on the market, works by controlling genes that may cause Parkinson’s. This happens when the drug interacts with a protein inside brain cells.

The team at the Oxford Parkinson’s Disease Centre used cutting-edge stem cell techniques to grow brain cells from skin cell samples donated by people with a rare genetic form of Parkinson’s, and from healthy people without the condition.

The team followed the progression of the condition in brain cells made from the patients’ stem cells and saw that a number of important genes became inactive when problems first started to occur inside the Parkinson’s-inflicted cells.

The “switching off” of these genes early in the process brought the condition on later.

Professor Caleb Webber of Oxford’s Department of Physiology, Anatomy and Genetics, who co-led the study, said: ‘This is the first time researchers have followed the progression of the condition over time in brain cells in the lab, something we simply cannot do in cells inside the living brain.’

Professor Richard Wade-Martins of Oxford’s Department of Physiology, Anatomy and Genetics, who co-led the study, said: ‘We think that switching off these genes in brain cells may play a vital role in the cell damage and death that occurs in Parkinson’s. Finding a way to ‘turn them back on’ with a drug could be a promising, unexplored way to develop new treatments.’

Deputy Director of Research at Parkinson’s UK, Professor David Dexter, said: ‘This study has opened up a new avenue of research and is a fantastic example of where cutting-edge technology is enabling the use of stem cells to show what may be causing Parkinson’s.

‘The study also highlights the growing number of drugs which can be repurposed from their original medical use to treat Parkinson’s. Developing a drug from scratch is a long, slow and expensive process. By finding existing drugs and moving them rapidly into clinical trials, we can make them available for people with Parkinson’s much more quickly, easily and cheaply.’

brain scans

The “switching off” of these genes early in the process brought the condition on later. NeuroscienceNews.com image is adapted from the Oxford University news release.

The team showed that turning the genes back on corrected cell changes in the Parkinson’s brain cells. The study was conducted using cells grown from people with a relatively rare form of Parkinson’s. To find out whether the results apply to all people with Parkinson’s, the team next studied brain cells grown from people with the more common, non-genetic form of the condition.

Professor Wade-Martins added: ‘We’ve only studied brain cells from eight individuals with ‘regular’ Parkinson’s so far so it’s early days, but initial findings indicate that the brain cells that share the same pattern of inactive genes and might also benefit from the same treatment.

‘Others, however, don’t. This may mean that tasquinimod may work for some people with Parkinson’s and not for others, and we are working on how to tell who will benefit.’

About this neuroscience research article

Funding provided by Parkinson’s UK.

Source: Oxford University
Publisher: Organized by NeuroscienceNews.com.
Image Source: NeuroscienceNews.com image is adapted from the Oxford University news release.
Original Research: Open access research for “Single-Cell Sequencing of iPSC-Dopamine Neurons Reconstructs Disease Progression and Identifies HDAC4 as a Regulator of Parkinson Cell Phenotypes” by Charmaine Lang, Kieran R. Campbell, Brent J. Ryan, Phillippa Carling, Moustafa Attar, Jane Vowles, Olga V. Perestenko, Rory Bowden, Fahd Baig, Meike Kasten, Michele T. Hu, Sally A. Cowley, Caleb Webber, and Richard Wade-Martins in Cell Stem Cell. Published November 29 2018.
doi:10.1016/j.stem.2018.10.023

Cite This NeuroscienceNews.com Article
Oxford University”Experimental Cancer Drug Shows Promise for Parkinson’s.” NeuroscienceNews. NeuroscienceNews, 3 December 2018.
<http://neurosciencenews.com/cancer-drug-parkinsons-120188/>.
Oxford University(2018, December 3). Experimental Cancer Drug Shows Promise for Parkinson’s. NeuroscienceNews. Retrieved December 3, 2018 from http://neurosciencenews.com/cancer-drug-parkinsons-120188/
Oxford University”Experimental Cancer Drug Shows Promise for Parkinson’s.” http://neurosciencenews.com/cancer-drug-parkinsons-120188/ (accessed December 3, 2018).

Abstract

Single-Cell Sequencing of iPSC-Dopamine Neurons Reconstructs Disease Progression and Identifies HDAC4 as a Regulator of Parkinson Cell Phenotypes

Induced pluripotent stem cell (iPSC)-derived dopamine neurons provide an opportunity to model Parkinson’s disease (PD), but neuronal cultures are confounded by asynchronous and heterogeneous appearance of disease phenotypes in vitro. Using high-resolution, single-cell transcriptomic analyses of iPSC-derived dopamine neurons carrying the GBA-N370S PD risk variant, we identified a progressive axis of gene expression variation leading to endoplasmic reticulum stress. Pseudotime analysis of genes differentially expressed (DE) along this axis identified the transcriptional repressor histone deacetylase 4 (HDAC4) as an upstream regulator of disease progression. HDAC4 was mislocalized to the nucleus in PD iPSC-derived dopamine neurons and repressed genes early in the disease axis, leading to late deficits in protein homeostasis. Treatment of iPSC-derived dopamine neurons with HDAC4-modulating compounds upregulated genes early in the DE axis and corrected PD-related cellular phenotypes. Our study demonstrates how single-cell transcriptomics can exploit cellular heterogeneity to reveal disease mechanisms and identify therapeutic targets.

Feel free to share this Neuroscience News.
Join our Newsletter
I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )
Sign up to receive the latest neuroscience headlines and summaries sent to your email daily from NeuroscienceNews.com
We hate spam and only use your email to contact you about newsletters. We do not sell email addresses. You can cancel your subscription any time.
No more articles